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Allergic asthma is a chronic infl  ammatory dis-
order of the lung with a prevailing T helper 
(Th)2 immune response to inhaled allergens 
leading to bronchial hyperreactivity, recruit-
ment of eosinophils, mast cells, and lympho-
cytes, and hyperplasia of smooth muscle and 
goblet cells, often associated with increased 
serum IgE concentrations (1). Central to the 
pathogenesis of allergic airway disease are 
  antigen-specifi  c memory T cell responses. Th2 
cells are recruited along concentration gradi-
ents of the thymus- and activation-regulated 
chemokine/CCL17 (TARC) (2) and produce 
the proallergic cytokines IL-4, IL-5, and IL-13. 
Th cells play an important role both in the ini-
tiation and challenge phases of allergic asthma, 
and understanding the mechanisms by which 
these cells respond to allergen challenges could 
lead to novel therapeutic approaches (3).
IL-17 (IL-17A), originally discovered as a 
close homologue of a protein of the T cell 
tropic Herpesvirus saimiri, is produced by the 
memory T cells termed Th17 (4–9), a Th cell 
lineage distinct from Th1 and Th2 cells, which 
is negatively regulated by IFN-γ and IL-4 
(10, 11). IL-17 is critical in the clearance of seve-
ral pathogens (12–14), and in vivo expression 
of IL-17 leads to expansion of hemopoietic pro-
genitors and neutrophilia (15), which, if un-
controlled, may lead to chronic and autoimmune 
infl  ammation such as encephalomyelitis, type 
II collagen–induced arthritis, and chronic en-
terocolitis (16–22).
Elevated IL-17 concentrations were found 
in the lung and blood of allergic asthma pa-
tients and linked to severity of asthma (23–28). 
However, the diff  erentiation of Th17 cells is 
induced by T regulator (T reg) cytokine TGF-β1, 
a regulator of the Th2 response (1, 29),  together 
with proinfl   ammatory cytokines (IL-6, IL-1, 
TNF, and IL-23) (30). In vitro investigations 
revealed that IL-17 inhibited CD4+ T cell ac-
tivation (31, 32), the expression of the chemo-
kines Rantes (CCL5), Fractalkine (CX3CL1), 
Interleukin-17 is a negative regulator 
of established allergic asthma
Silvia Schnyder-Candrian,1,2 Dieudonnée Togbe,1 Isabelle Couillin,1 
Isabelle Mercier,1 Frank Brombacher,4 Valérie Quesniaux,1 
Francois Fossiez,3 Bernhard Ryff  el,1 and Bruno Schnyder1,2
1Université d’ Orléans, Centre national de la Recherche Scientifi  que (CNRS), Molecular Immunology and Embryology, 45071 
Orléans, France
2Biomedical Research Foundation, SBF, 9548 Matzingen, Switzerland
3Schering Plough Inc., 69571 Dardilly, France
4Institute of Infectious Disease and Molecular Medicine, University of Cape Town, 7925 Cape Town, South Africa
T helper (Th)17 cells producing interleukin (IL)-17 play a role in autoimmune and allergic 
infl  ammation. Here, we show that IL-23 induces IL-17 in the lung and IL-17 is required 
during antigen sensitization to develop allergic asthma, as shown in IL-17R–defi  cient mice. 
Since IL-17 expression increased further upon antigen challenge, we addressed its function 
in the effector phase. Most strikingly, neutralization of IL-17 augmented the allergic 
  response in sensitized mice. Conversely, exogenous IL-17 reduced pulmonary eosinophil 
recruitment and bronchial hyperreactivity, demonstrating a novel regulatory role of IL-17. 
Mechanistically, IL-17 down modulated eosinophil-chemokine eotaxin (CCL11) and thymus- 
and activation-regulated chemokine/CCL17 (TARC) in lungs in vivo and ex vivo upon antigen 
restimulation. In vitro, IL-17 reduced TARC production in dendritic cells (DCs)—the major 
source of TARC—and antigen uptake by DCs and IL-5 and IL-13 production in regional lymph 
nodes. Furthermore, IL-17 is regulated in an IL-4–dependent manner since mice defi  cient 
for IL-4R𝗂 signaling showed a marked increase in IL-17 concentration with inhibited eo-
sinophil recruitment. Therefore, endogenous IL-17 is controlled by IL-4 and has a dual role. 
Although it is essential during antigen sensitization to establish allergic asthma, in sensitized 
mice IL-17 attenuates the allergic response by inhibiting DCs and chemokine synthesis.
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and CTACK (CCL27), and vascular cell adhesion molecule-1 
in TNF-activated mesenchymal cells, interfering with the 
IFN-responsive factor-1 transcription factor and NF-κB ac-
tivities (33–36). Based on our fi  ndings that IL-17 conveys 
dual eff  ects (stimulation of proinfl  ammatory cytokines and 
down-regulation of chemokines) in fi  broblasts with the in-
hibitory IL-17 eff  ect prevailing at low concentrations (36), 
we hypothesized a regulatory role of IL-17 in vivo and inves-
tigated the potential of IL-17 for regulating the Th2 response 
to inhaled allergens.
We document here a dual eff  ect of IL-17 in allergic 
asthma: it is required for induction but negatively regulates 
established asthma. We show in vitro for the fi  rst time that IL-
17 inhibits chemokine TARC production by DCs, which 
play a key role in the Th2 response and therefore in allergic 
asthma (37). Mucosal IL-17 administration inhibited asthma 
by reducing the pulmonary production of IL-5 and the che-
mokines TARC and eotaxin, which control eosinophil re-
cruitment and asthma. Neutralizing IL-17 antibodies increased 
asthma, further demonstrating that IL-17 is present during 
the allergic response as a negative regulator of asthma.
RESULTS
IL-17 is required in the initiation of allergic asthma
To investigate the role of IL-17 in allergic asthma we fi  rst 
used receptor IL-17R gene–defi  cient (IL-17R KO) mice 
in an OVA-induced model of asthma. Reduced lung and 
airway recruitment of granulocytes, predominantly eosino-
phils, were found in IL-17R KO mice compared with WT 
mice (Fig. 1, A and B). Furthermore, eosinophil peroxidase 
(EPO) activity in lung tissues (Fig. 1 C) and OVA-specifi  c 
serum IgE concentrations were reduced (Fig. 1 D) in the 
absence of IL-17R signaling. The reduced asthma like se-
quellae of antigen challenge in IL-17R KO compared with 
WT mice correlates with a reduced regional Th2 cytokine 
production. Regional lymph nodes from antigen-sensitized 
and intranasally challenged mice were restimulated ex vivo 
(in cell culture), resulting in reduced IL-5 production in 
cells from IL-17R KO compared with WT mice (Fig. 1 E). 
The composition of CD3+, CD11b+, and CD11c+ lymph 
node cells was similar in IL-17R KO and WT mice (Fig. 
1 F), indicating that reduced antigen-induced cell activation 
rather than recruitment of immune cells to the lymph nodes 
of IL-17R KO mice causes attenuated Th2 responses. 
Therefore, signaling through IL-17R is critically required to 
develop allergic asthma.
Figure 1.  Role of IL-17 in development of allergic infl  ammation, 
as assessed in receptor IL-17R KO mice. OVA/alum-sensitized C57BL/6 
mice (WT) and IL-17R KO (IL-17R−/−) mice were challenged three times 
intranasally with OVA. 48 h after the third challenge, the BAL cells and 
eosinophils were counted (A and B), and lung tissue activities of EPO (C) 
and OVA-specifi  c serum IgE concentrations (D) were determined. Medias-
tinal lymph nodes (MLNs) were removed from antigen-sensitized and 
challenged mice, restimulated in vitro with 50 μg/ml OVA, and analyzed 
for IL-5 production (E). In F, the cell composition of freshly excised MLNs 
was determined by FACS analysis. The percentages of CD3-, CD11b- and 
CD11c-positive cells are shown. The bars represent the mean ± SD (n = 8 
animals per group). *, P ≤ 0.05; dotted line indicates basal levels.
Figure 2.  IL-17 is induced in the lung upon allergen challenge. 
Mice were sensitized and challenged with OVA, and IL-17 and IL-23 were 
determined by ELISA in the lung homogenate (A and B). In naive, nonsen-
sitized mice, no IL-17 was detected (A). In C and D, cells from mediastinal 
lymph nodes (MLNs) or splenocytes of sensitized and challenged mice 
were restimulated in vitro with 300 ng/ml IL-23. The bars represent the 
mean ± SD (n = 8 animals per group). n.d., not detected. *, P ≤ 0.05; 
dotted line indicates basal levels.JEM VOL. 203, November 27, 2006  2717
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airways hyperreactivity and infl  ammation.   Recombinant mu-
rine IL-17 (0.1 μg) given together with the OVA challenge 
inhibited methacholine response by 58 ± 18% (P < 0.03; Fig. 
3 A), and this eff  ect was similar at high IL-17 dose (10 μg). 
Moreover, the response of mice sensitized with OVA plus ad-
juvant aluminium hydroxide and challenged intranasally with 
OVA was also reduced by IL-17 (unpublished data).
IL-17–induced inhibition of methacholine response was 
fully reversed by neutralizing IL-17 antibody treatment (Fig. 
3 A), confi  rming the specifi  city of exogenous IL-17 eff  ect. 
IL-17 antibody administration augmented the methacholine 
response above controls (P < 0.01) (Fig. 3 A, bar 5 vs. 3), sug-
gesting that endogenous IL-17 was also neutralized and con-
tributed to methacholine response.
IL-17 did not inhibit systemic OVA-specifi  c serum IgE 
concentrations, which refl  ect intact T cell–B cell interac-
tions (Fig. 3 B). Therefore, the data suggest that IL-17 given 
with antigen challenge has an inhibitory eff  ect on methacho-
line response.
IL-17 is induced in the lung upon local allergen challenge
Pulmonary IL-17 was induced in allergen-sensitized com-
pared with nonsensitized mice and further increased upon 
intranasal challenge (Fig. 2 A). IL-17 production correlated 
with pulmonary IL-23 induction (Fig. 2 B). In cell cultures 
derived from allergen-sensitized and challenged mice, IL-23 
was able to induce IL-17 in mediastinal lymph node (Fig. 2 C) 
but not in splenocyte cultures (Fig. 2 D), suggesting a local 
pulmonary role of IL-17. Therefore, we show in a model of 
allergic asthma that IL-17 is locally augmented by allergen 
challenge and induced by IL-23.
Exogenous IL-17 reduces methacholine response 
upon antigen challenge
OVA-sensitized C57BL/6 mice challenged intranasally with 
OVA, but not NaCl or IL-17 alone, developed a robust  response 
to aerosolized methacholine given in enhanced   respiratory 
pause (Penh) values (Fig. 3 A) (38). Penh   values measured 
provide an estimate for airway obstruction and may indicate 
Figure 3.  Exogenous IL-17 inhibits methacholine response upon 
allergen challenge. OVA-sensitized C57BL/6 mice were challenged intra-
nasally with either saline, OVA alone, IL-17 alone, OVA with IL-17, or OVA 
with IL-17 plus neutralizing IL-17 antibodies. 24 h after the challenges, 
the methacholine response was measured using whole-body plethysmog-
raphy. The intensity is measured in Penh arbitrary units, and the calcu-
lated area under the Penh time-curves (AUC) is shown. 48 h after the 
third challenge, OVA-specifi  c serum IgE concentrations were determined, 
given in absorbance (OD 405 nm) values (B), and the BAL cells were 
counted. Eosinophil, lymphocyte, macrophage, and neutrophil counts (C) 
are presented. The same effect of IL-17 was found in mice sensitized 
with OVA/alum (unpublished data). The results represent the mean ± SD 
of n = 8 animals per group. *, P ≤ 0.05; dotted line indicates 
basal levels.2718  IL-17 DOWN-REGULATES ASTHMA | Schnyder-Candrian et al.
Figure 4.  IL-17 inhibits cell recruitment to the lungs and mucus 
hypersecretion. Lung sections of OVA-sensitized C57BL/6 mice killed 2 d 
after the third challenge with either saline, OVA, OVA with IL-17 antibod-
ies, OVA with IL-17, or OVA with IL-17 plus IL-17 antibodies are shown. 
The formalin-fi  xed tissue sections were stained with hematoxylin and 
eosin to visualize cell recruitment (A) and with periodic acid Schiff re-
agent (PAS) to visualize mucus (B), as shown by the arrows. Bars, 200 μm. 
In C and D, the histology sections were quantitated for eosinophil recruit-
ment and mucus hypersecretion, respectively. A score scale from 0 to 5 is 
given on the y axis. The EPO in the lung tissue homogenates was deter-
mined 48 h after the last challenge, given in OD values (OD 490 nm) (E). 
The results represent the mean ± SD of n = 8 animals per group. 
n.d., not detected. *, P ≤ 0.05; dotted line indicates basal levels.
IL-17 decreases lung eosinophil recruitment
We then investigated the regulatory role of IL-17 in antigen-
induced lung infl  ammation. 24 h after  methacholine  response 
analysis, infl  ammatory cell recruitment into the lung tissue 
and the alveolar space was analyzed (Fig. 3 C). The total 
bronchoalveolar lavage (BAL) cell numbers increased up 
to 24-fold in OVA-challenged compared to saline-treated 
  control mice (15 × 104 to 354 × 104 cells/BAL). The JEM VOL. 203, November 27, 2006  2719
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higher cell number was mainly caused by eosinophil re-
cruitment, increasing more than 700-fold (P < 0.01; 
Fig. 3 C).
IL-17 administration at 0.1 μg signifi  cantly reduced the 
total BAL cells by 91% (P < 0.01), the eosinophil counts by 
95% (P < 0.01; Fig. 3 C), and lymphocyte counts by 84% 
(P < 0.01; Fig. 3 C). These regulatory IL-17 eff  ects were 
fully   reversed by the administration of neutralizing IL-17 
anti  body (Fig. 3 C, bar 4). IL-17 antibody administration 
  augmented eosinophil counts above controls (P < 0.01) 
(Fig. 3 C, bar 5 vs. 2), suggesting that endogenous IL-17 was 
also neutralized, which contributed to eosinophil recruit-
ment. Application of isotype-matched control antibody with 
the OVA challenge had no eff  ect on OVA-induced response 
(unpublished data).
Microscopically the lung tissue of OVA-challenged 
mice showed peribronchial cell recruitment together with 
hyperplasia of bronchial smooth muscle. IL-17 reduced 
peribronchial eosinophil infi  ltration and the mucus hyper-
secretion and hyperplasia of goblet cells (Fig. 4, A and B) 
from 4 to 1 using scoring scale from 0 to 5 (Fig. 4, 
C and D). Reduction of eosinophil infi  ltration correlated 
with   reduced EPO activity in the lung tissue of IL-17–
treated animals (Fig. 4 E). These eff  ects were reversed by 
neutralizing IL-17 antibodies. Neutralizing IL-17 antibod-
ies given alone to OVA-challenged mice augmented eosin-
ophil infi  ltration and mucus secretion above OVA-challenged 
controls (Fig. 4, C and D, bar 5 vs. 2), suggesting that 
  endogenous IL-17 was also neutralized, which contributed 
to pathology.
IL-17 inhibits pulmonary CC-chemokine expression in vivo
CC-chemokines, eotaxin, Rantes, and TARC, contribute to 
allergic infl  ammation, as demonstrated in neutralization ex-
periments and gene-defi  cient mice (39–41). IL-17 reportedly 
inhibits Rantes expression in TNF-stimulated lung fi  broblasts 
and in colonic myofi  broblasts (33, 36). We tested whether 
IL-17 inhibits the mononuclear cell–chemokine production 
in allergic lungs.
OVA-sensitized and intranasally challenged mice showed 
increased TARC, eotaxin, and Rantes production in the 
lung tissue (Fig. 5). Exogenous IL-17 abolished TARC and 
eotaxin expression completely and reduced Rantes induction 
by 50% (Fig. 5, A–C). As expected, the inhibition was largely 
reversed by neutralizing IL-17 antibody treatment (Fig. 5), 
demonstrating the specifi  city of the IL-17 eff  ects. Neutraliz-
ing IL-17 antibodies given alone to OVA-challenged mice 
augmented TARC expression above OVA-challenged con-
trols (Fig. 5, A and B, bar 2 vs. 3), suggesting that endogenous 
IL-17 also aff  ects TARC production.
In the allergen-infl  amed BAL, TARC (Fig. 5 A), but nei-
ther eotaxin nor Rantes (unpublished data), were   detected. 
Reduced TARC production correlated with reduced lym-
phocyte and eosinophil counts. Our fi   ndings suggest that 
IL-17 attenuates antigen-induced asthma by inhibiting the pro-
duction of CC-chemokines, TARC, eotaxin, and Rantes.
IL-17 decreases CC-chemokine expression in lung explant 
cell culture and inhibits DC function
IL-17–mediated inhibition of the chemokines TARC and 
eotaxin observed in vivo was consolidated in cell cultures. 
Mice were sensitized, intranasally challenged with OVA, 
and 2 d after the last challenge lung explant cell cultures, 
mediastinal lymph node cells, and splenocyte cultures thereof 
were restimulated ex vivo with 50 μg/ml OVA in the 
presence or absence of IL-17 (Fig. 6). In lung explant cell 
cultures, IL-17 reduced spontaneous and OVA-induced ex-
pression of eotaxin and TARC (Fig. 6, A and C). In lung 
macrophages, specifi  cally eotaxin (Fig. 6 D), but not TARC 
(Fig. 6 B), was expressed,  implying that TARC may be 
expressed by nonadherent leukocytes, likely DCs, a major 
source of TARC.
Therefore, we analyzed whether IL-17 reduces DC func-
tions. TARC was produced in unstimulated and TNF-activated 
Figure 5.  IL-17 inhibits pulmonary contents of the mononuclear cell 
attracting chemokines TARC, eotaxin and Rantes. OVA-sensitized 
C57BL/6 mice were challenged three times intranasally with either saline, OVA 
alone, OVA plus IL-17–neutralizing antibodies, OVA with IL-17, or OVA with 
IL-17 plus IL-17 antibodies. 48 h after the third challenge, BAL was performed 
and the lung tissues were excised. The chemokine contents in the liquid phase 
of the lung homogenate and in the BAL were measured by ELISA specifi  c for 
TARC (A), eotaxin (B), and Rantes (C). The results represent the mean ± SD 
(n = 8 animals per group). *, P ≤ 0.05; dotted line indicates basal levels.2720  IL-17 DOWN-REGULATES ASTHMA | Schnyder-Candrian et al.
bone marrow–derived DCs (CD11c+) (Fig. 7 A) but not in 
bone marrow–derived macrophages (CD11c−) (Fig. 7 B). IL-17 
reduced spontaneous and TNF-induced expression of TARC 
(Fig. 7 A). Furthermore, dendritic antigen uptake of  fl  uorescence-
labeled OVA was reduced by IL-17 by 46% (Fig. 7 C).
Therefore, the data show that IL-17 reduces TARC and 
eotaxin expression directly in lung cells, providing a key eff  ec-
tor mechanism of how IL-17 inhibits allergy in vivo. The ab-
sence of TARC production upon OVA stimulation in regional 
lymph node and splenocyte cultures (Fig. 8) supports the rele-
vance of TARC in lungs rather than lymphoid organs.
IL-17 reduces Th2 cytokine production
Since IL-17 reduces functions of the APCs, the DCs, we ad-
dressed whether IL-17 reduces antigen-induced Th2 cyto-
kine production in vivo and in cell cultures. In vivo, IL-17 
reduced allergen-induced IL-5 production in lung tissues by 
72 ± 6% (P < 0.05) and in the BAL fl  uid by 100% from 
54.3 ± 29.8 pg/ml to below detection limit (1 pg/ml). BAL 
IL-4 concentrations were reduced by 98 ± 0.5% in the pres-
ence of IL-17, from 13.0 ± 3.3 pg/ml to 0.3 ± 0.5 pg/ml. 
The Th2 cytokine expression of IL-5 and IL-13 in restimu-
lated regional lymph node cell cultures was also inhibited 
by IL-17 by >50% (Fig. 8, A and B) but not in splenocyte 
cultures (Fig. 8, E and F). Similarly, IL-17 reduced OVA-
  induced Rantes expression by regional lymph node cells (Fig. 
8 D) but not splenocyte cultures (Fig. 8 H). Therefore, the data 
show that IL-17 markedly inhibits antigen-stimulated lung 
and regional lymph node cells, providing a key target mecha-
nism of how IL-17 inhibits allergy.
IL-17 was augmented in IL-4R𝗂 KO mice and reduced 
allergic asthma
Since IL-4 signaling has a major eff  ect on the allergic re-
sponse (42) and has been implicated in vitro to act on Th17 
development (10, 11), we addressed the question of whether 
IL-4Rα KO mice have altered IL-17 expression. Allergen 
challenge in IL-4Rα KO mice increased IL-17 concentra-
tions from 20 ± 4 pg/ml in WT mice to 32 ± 7 pg/ml (Fig. 
9 A). Pulmonary IL-23 concentrations upon OVA challenge 
were equal in IL-4Rα KO and WT mice, indicating that 
IL-4 acts directly on IL-17 production (unpublished data).
IL-4Rα KO mice had reduced chemokine TARC pro-
duction and allergic infl   ammation upon OVA challenge. 
Blocking of endogenous IL-17 by neutralizing antibodies 
  reversed the reduced pulmonary TARC production, eosino-
phil recruitment to the airways, and EPO activity in the lungs 
in IL-4Rα KO mice (Fig. 9, B–D). This indicates that the in-
hibition of asthma in IL-4Rα KO mice is partially caused by 
endogenous IL-17. This marked eff  ect of endogenous IL-17 
in IL-4Rα KO confi  rms the eff  ect found on TARC expres-
sion of endogenous IL-17 in WT mice shown in Fig. 5.
In parallel, IL-17 neutralization reduced neutrophil 
  recruitment to the airways, myeloid peroxidase activity in 
the lungs, and neutrophil chemokine KC production. This 
Figure 6.  IL-17 inhibits TARC and eotaxin production ex vivo in 
lung explants. Lung explants (A and C) and lung adherent cells (B and D) 
were prepared from OVA-sensitized and challenged animals. Cells were 
treated with saline, 50 μg/ml OVA alone, IL-17 alone, or OVA plus 30 ng/ml 
IL-17 for 24 h. The concentrations of TARC (A and B) and eotaxin (C and D) 
were measured by ELISA. In lung cell cultures of naive, nonsensitized 
mice no TARC was detected (A). The results represent the mean ± SD 
of 8 animals per group. n.d., not detected. *, P ≤ 0.05.
Figure 7.  IL-17 inhibits TARC production and OVA uptake in DCs. 
DCs (A and C) and macrophages (B) were differentiated in vitro from 
naive bone marrow–derived cells. Cells were treated with saline, IL-17 
alone, 3 ng/ml TNF, or TNF with 30 ng/ml IL-17 for 24 h. The concentrations 
of TARC (A and B) were measured by ELISA. The results represent the mean 
± SD of 8 animals per group. In C, uptake of 100 μg/ml OVA-FITC by DCs 
in the absence and presence of IL-17 (+IL-17) was analyzed by FACS. 
A histogram is shown in the left panel. The mean fl  uorescence intensity (MFI) 
thereof is given in the right hand panel. n.d., not detected. *, P ≤ 0.05.JEM VOL. 203, November 27, 2006  2721
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demonstrates that augmented neutrophil recruitment in IL-
4Rα KO mice is partially caused by endogenous IL-17 (Fig. 
9, E–G). These data suggest a novel down-regulatory role of 
endogenous IL-17 in the eff  ector phase of allergic asthma, 
which may, however, be accompanied by increased neutro-
phil accumulation in the absence of IL-4 signaling.
DISCUSSION
We demonstrate a novel, negative regulatory function of IL-
17 in allergic asthma in mice. During local antigen challenge, 
pulmonary IL-17 production was enhanced and reduced the 
hallmarks of allergic asthma, lung infl  ammation and dysfunc-
tion, and epithelial mucus hypersecretion. Mechanistically, 
Figure 8.  IL-17 inhibits IL-5, IL-13, and Rantes production in me-
diastinal lymph nodes (MLNs). MLN (A–D) and splenocyte (E–H) cul-
tures were prepared from OVA-sensitized and challenged animals. Cells 
were treated with saline, 50 μg/ml OVA alone, IL-17 alone, or OVA plus 
30 ng/ml IL-17 for 24 h. The concentrations of IL-5, IL-13, TARC, and 
  Rantes were measured by ELISA. The results represent the mean ± SD of 
8 animals per group. n.d., not detected. *, P ≤ 0.05; dotted line indicates 
basal levels.
Figure 9.  IL-4 signaling suppresses pulmonary IL-17 production. 
OVA/alum-sensitized BALB/c mice (WT) and IL-4Rα KO (IL4R−/−) mice 
were challenged twice intranasally with either saline or OVA alone. In 
parallel, the IL-4Rα KO mice were challenged with OVA plus neutralizing 
anti–IL-17 antibodies. 48 h after the last challenge, IL-17, TARC, and KC 
concentrations in the lung homogenates were measured by ELISAs (A, B, 
and E), and the cells infi  ltrating the BAL were counted (C and F). Lung 
tissue activities of EPO and myeloperoxidase (D and G). The results repre-
sent the mean ± SD of 8 animals per group. 2722  IL-17 DOWN-REGULATES ASTHMA | Schnyder-Candrian et al.
IL-17 administration reduced allergen-induced production 
of the Th2 lymphocyte-attracting chemokine TARC, eosin-
ophil-attracting chemokine eotaxin, and IL-5, which related 
to reduced lymphocyte and eosinophil recruitment. Inhibi-
tion of chemokines TARC, eotaxin, and Rantes reportedly 
reduce allergic asthma, as demonstrated in experimental neu-
tralization or gene-defi  cient mice (39–41). Therefore, these 
data suggest that IL-17 is a negative regulator of the eff  ector 
phase of asthma.
T reg cells promote under proinfl  ammatory conditions 
and in presence of IL-23 the development of Th17 cells and 
production of IL-17 (30). Here we show that IL-17 is a 
downmodulator of the DC-derived Th2 chemoattractant 
TARC, providing evidence for a novel feedback mechanism 
by which T reg cells may control a Th2 response in the ef-
fector phase of allergic asthma.
IL-17 had an inhibitory eff  ect on the local production of 
the Th2 cytokines IL-4, IL-13, and IL-5 in the lung and re-
gional lymph nodes, but not in splenocyte cultures. Together 
with the fi  nding that IL-17 inhibited TARC production of 
DCs, a Th2 chemoattractant (2), we conclude that IL-17 acts 
on DC activation and antigen uptake, which leads to reduced 
activation of T cells and reduced IL-4, IL-13, and IL-5 pro-
duction, resulting in reduced allergic response (37).
Although we describe a novel function of IL-17 in the 
resolution of allergic asthma, we also confi  rm its previously 
reported role in initiating allergic asthma (43) and inducing 
neutrophil recruitment. High neutrophil recruitment and 
KC expression was particularly seen in IL-4Rα KO mice that 
express markedly high concentration of IL-17. These proal-
lergic and infl  ammatory roles could be explained by IL-17–
inducing hematopoietic colony-stimulating factors (12), 
antigen activation of T cells (44), and production of neutro-
phil-chemokines KC and IL-8 (CXC) (33–36).
Increased IL-17 concentrations in allergic asthma, chronic 
bronchitis, chronic obstructive pulmonary disease, cystic fi  -
brosis, and acute respiratory distress syndrome (for review see 
references 9, 26), but also rheumatoid arthritis, were linked 
to the pathology of the diseases (18). IL-17 neutralization in-
hibits experimental murine arthritis (17, 18) and is a potential 
alternative therapy to TNF neutralization in rheumatoid ar-
thritis. Our data indicate, however, that such a therapy bears 
the potential risk of exacerbating allergic infl  ammation. On 
the other hand, neutralization of Th2 cytokines is a therapeu-
tic strategy to reduce allergic asthma, for example, by using 
neutralizing IL-4 and IL-13 antibodies or soluble IL-4Rα 
molecules (45, 46). Here we show that allergic asthma is re-
duced in mice lacking the IL-4 signal transduction mecha-
nisms through receptor IL-4Rα, as also shown in mice 
defective for transcription factor Stat6 (47, 48), but that this 
is associated with increased pulmonary neutrophil recruit-
ment and IL-17 production. Inhibition of the neutrophil in-
fi  ltration by neutralizing IL-17 antibodies was associated with 
elevated eosinophil infi   ltration in the allergic response in 
vivo. Therefore, the regulation of IL-17 directly infl  uences the 
nature of the cellular recruitment at the site of infl  ammation, 
and IL-17 represents an eff  ector molecule regulating neutro-
phil and eosinophil infi  ltration. Here, we provide a mechanistic 
understanding of the proallergic eff  ects mediated by IL-4Rα, 
through down-regulation of IL-17, which we identify as a 
negative regulator of asthma.
In contrast to the control of eosinophil infi  ltration, antigen-
specifi  c IgE production was not aff  ected by IL-17 adminis-
tered during the antigen challenge, which indicates intact 
T and B cell interactions and adaptive immunity to the allergen. 
IgE elevations reportedly correlate with and contribute to 
  allergic reactions (49), although they are not suffi   cient for the 
development of allergy. Intact antigen-specifi  c IgE concen-
trations in the current study may explain why IL-17 did not 
completely block but rather reduced allergy.
Th17 cell–derived IL-17 expression is further induced in 
an established allergic response together with IL-23 and con-
trolled by IL-4Rα signals. Although neutralizing IL-17 anti-
bodies augmented an established allergic response, IL-17 
reduced the response by inhibiting dendritic functions, 
TARC, IL-4, and IL-5 expression. Therefore, the data dem-
onstrate that IL-17 is a novel endogenous negative regulator 
of allergic asthma, and IL-17 or Th17 cells may represent an 
interesting therapeutic target in asthma.
MATERIALS AND METHODS
Materials. O-phenylenediamine, 3-amino-1,2,4-triazole, horseradish per-
oxidase, and bovine serum albumin grade V were obtained from Sigma 
Chemical Company. Mouse recombinant IL-17 and anti–IL-17 neutralizing 
monoclonal antibody were provided by Schering Plough and R&D Systems. 
The antibodies used for FACS analysis, PE–anti-CD3 (clone 145-2C11), 
APC–anti-CD11b (clone M1/70), FITC–anti-CD11c (HL3), isotype-
matched control antibodies for FACS analysis, and isotype-matched control 
antibody IgG1a for in vivo application were purchased from BD Biosciences. 
Human IL-23 was provided by Di Padova (Novartis, Basel, Switzerland). 
FITC-conjugated OVA was purchased from Molecular Probes.
Mice. C57BL/6, BALB/c mice WT, and receptor IL-4Rα KO mice 
were bred in our specifi  c pathogen-free animal facility at CNRS. Recep-
tor IL-4Rα KO mice were on BALB/c genetic background as described 
previously (46). Receptor IL-17R KO mice were on C57BL/6 genetic 
background as described previously (46) and provided by Amgen. Mice 
were maintained in a temperature-controlled (23°C) facility with a strict 
12-h light–dark cycle and were given free access to food and water. The 
experiments were performed with gender-matched mice aged 6–8 wk. 
All protocols complied with the French Government’s ethical and animal 
experiment regulations.
Experimental protocol. Mice were sensitized s.c. twice at weekly inter-
vals with 0.4 ml saline containing 10 μg OVA with 1.6 mg aluminium 
  hydroxide. Mice were also sensitized with 10 μg OVA without adjuvant 
  aluminium hydroxide, yielding the same results as in the presence of alu-
minium hydroxide. 1 wk after the second immunization, C57BL/6 mice 
were challenged three times (at days 14, 16, and 18) and BALB/c mice were 
challenged twice (at days 14 and 16) as follows. Animals were hold under 
light i.v. Ketamine/Xylazine anesthesia and administered intranasally with 
40 μl saline (0.9%) containing 10 μg OVA alone, or 10 OVA with 0.1 μg 
IL-17, or OVA with 5 μg anti–IL-17 antibodies, or OVA with 0.1 μg IL-17 
and 5 μg anti–IL-17 antibodies. Control mice were challenged with saline 
alone, or IL-17 alone, given in 40 μl saline solution. The doses of exogenous 
IL-17 applied were estimated from a previous in vivo study in rat neuritis 
(50). 1 d after the last challenge, plethysmography analysis was performed. JEM VOL. 203, November 27, 2006  2723
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1 and 2 d after the last challenge, respectively, BALB/c and C57BL/6 mice 
were killed and the lungs were analyzed.
Mice were given a high dose of Ketamine/Xylazine i.p. and bled out. Via 
a tracheal canula, the lungs were washed four times with 0.5 ml ice-cold PBS 
(see BAL section). After BAL, the lung was perfused via heart puncture with 
ISOTON II Acid free balanced electrolyte solution (Beckman Coulter). Half 
of the lung was stored at −80°C for EPO enzyme analysis, and the other half 
was fi  xed overnight in buff  ered 4% formaldehyde solution for histology analy-
sis. BAL fl  uid was analyzed for cell composition and cytokine concentrations. 
Experiments were performed at least twice using groups of four animals.
FACS. Mediastinal lymph node cells, derived from antigen-sensitized and 
challenged WT or IL-17R KO mice, were saturated with normal mouse 
  serum before staining with fl  uorescence-conjugated antibodies for 60 min. 
Cells were washed three times in PBS/1% BSA and analyzed using a FACS-
Calibur-Flow cytometer and CellQuest Software (Becton Dickinson). The 
markers for the monovariant histogram (unpublished data) were set based on 
the negative staining control using isotype-matched control antibodies.
Plethysmography. Response to aerosolized methacholine was investigated 
at 24 h after the last OVA challenge. Unrestrained conscious mice were 
placed in whole-body plethysmography chambers (Buxco Electronic). 
C57BL/6 mice were exposed for 50 s to increasing methacholine concentra-
tions (15, 50, and 150 mM), with 5-min intervals between the nebulizations. 
BALB/c mice were exposed for 50 s to 100 mM methacholine. The re-
sponse was measured for 15 min after nebulization.
Penh measurement can be conceptualized as the phase shift of the 
  thoracic fl  ow and the nasal fl  ow curves; increased phase shift correlates with 
increased respiratory system resistance. Penh is calculated by the formula 
Penh = (Te/RT-1) × PEF/PIF, where Te is expiratory time, RT is relax-
ation time, PEF is peak expiratory fl  ow, and PIF is peak inspiratory fl  ow. For 
the graphics, the Penh mean values are given for −3 to −1 min (base line) 
and 14 points or minutes after the methacholine nebulization. The area un-
der the curve was calculated as the sum of all Penh values minus the average 
of the base line values.
BAL. BAL fl  uids were prepared by washing the lungs four times with 0.5 ml 
ice-cold PBS. The cells were sedimented by centrifugation at 400 g for 
10 min at 4°C. The supernatant (cell-free BAL fl  uid) of the fi  rst lavage was 
stored at −70°C for cytokine analysis. An aliquot of the cell pellets was 
stained with Turk’s solution, counted, and 200,000 cells were centrifuged on 
microscopic slides (cytospin at 1,000 rpm for 10 min, at RT). Air-dried 
preparations were fi  xed and stained with Diff  -Quik (Merz & Dade A.G.). 
Diff  erential counts were made under oil immersion microscopy. 100 cells 
were counted twice for the determination of the relative percentage of each 
cell type present in the BAL.
Lung histology. The organs were fi   xed in 4% buff  ered  formalde-
hyde overnight and embedded in paraffi     n as described previously (51). 
Lung sections of 3 μm were stained with hematoxylin and eosin or 
with periodic acid Schiff   reagent and examined with a Leica microscope 
(×40 and ×100 magnifi   cation). Peribronchial infi   ltrates and smooth 
  muscle hyperplasia were assessed by a semiquantitative score (0–5) by two 
observers independently.
Pulmonary EPO activity. EPO activity was determined to estimate 
the recruitment of eosinophils to the lung parenchyme. After BAL lavage 
and perfusion (see Experimental protocol), the lungs were excised, homo-
genized for 30 s in 1 ml of 0.05 M Tris-HCl buff  er (pH 8.0) using 
a Polytron (Kinematic AG), and 0.1% (vol/vol) Triton X-100 added. 
The homogenate was centrifuged for 15 min at 4°C at 10,000 g. EPO 
  activity in the supernatant was determined as estimated from the oxidation 
of O-phenylenediamine by EPO in the presence of hydrogen peroxide 
(H2O2) using the protocol by Van Oosterhout et al. (52). The substrate 
  solution consisted of 10 mM O-phenylenediamine in 0.05 M Tris-buff  er 
(pH 8.0) and 4 mM H2O2 (BDH). Substrate solution was added to samples 
in a 96-well microplate and incubated at room temperature for 30 min be-
fore stopping the reaction by addition of 4 M sulfuric acid. Duplicate incu-
bations were performed in the absence and presence of the EPO inhibitor 
3-amino-1,2,4-triazole (2 mmol/l). The absorbance was then measured at 
492 nm (Flow Labs). Results are expressed as OD 492 nm and were cor-
rected for the activity of other peroxidases, which were not inhibited by 
3-amino-1,2,4-triazole.
Quantifi  cation of IL-17, IL-23, IL-5, IL-13, KC, Rantes, eotaxin, 
and TARC. Cytokine and chemokine concentrations in BAL, lung ho-
mogenate, or cell culture supernatants were determined by ELISA using 
commercial kits from R&D Systems. The lungs were homogenized for 
1 min using a Polytron (Kinematic AG), and the cell debris were eliminated 
by centrifugation at 10,000 g for 10 min. The cytokines were determined in 
the supernatants. The cytokine detection limit was 1 pg/ml.
Splenocytes and draining lymph node cultures. Murine spleens or 
draining lymph nodes (mediastinal) were taken into suspension by passing 
them through 100 μm mesh. The cells were washed once with PBS by cen-
trifugation for 10 min at 1,300 rpm. Erythrocytes were lysed by a short hy-
potonic shock with water in the case of splenocytes but not of lymph nodes. 
The cells were washed twice with cold PBS, counted, and the cell pellet was 
resuspended at 106 cells per ml in culture medium consisting of RPMI sup-
plemented with 10% FCS and 100 U/ml penicillin/streptomycin. The cells 
were cultivated in 24-well plates, 1-ml cell suspension per well, with the 
  indicated stimuli for 24 h at 37°C in a humidifi  ed incubator with 5% CO2.
Lung explant cultures. Lungs were excised, minced, and digested for 2 h 
in a HBSS solution containing 200 U/ml of collagenase II (GIBCO BRL), 
50 U/ml DNase I, 100 U/ml penicillin, and 100 μg/ml streptomycin (53). 
The homogenate was passed through 100 μm pore size fi  lters, and the cell 
suspension was washed three times with PBS supplemented with 2% FCS, 
100 U/ml penicillin, and 100 μg/ml streptomycin, and centrifuged at 200 g. 
The pellet was resuspended at 106 cells per ml in culture medium consisting 
of DMEM supplemented with 10% FCS and 100 U/ml penicillin/strepto-
mycin. The cells were cultured in 24-well plates, in 1 ml cell suspension per 
well with the stimuli indicated, for 24 h at 37°C in a humidifi  ed incubator 
with 5% CO2.
Adherent lung macrophages were obtained by adhering cells of lung 
explants for 2 h. Nonadhering cells were removed by washing three times 
with medium. 5 × 105 cells per well were cultured in 24-well plates in cul-
ture medium consisting of DMEM supplemented with 10% FCS and 100 
U/ml penicillin/streptomycin.
Bone marrow–derived DCs and macrophages. Murine bone marrow 
cells were isolated from femurs and diff  erentiated into myeloid DC by cul-
turing at 2 × 105 cells/ml for 10 d in RPMI medium supplemented with 
10% FCS, nonessential amino acids, 0.05 μg/ml asparagine, MEM vitamins, 
sodium pyruvate, gentamycin 50 μg/ml, 10,000 U/ml penicillin, 10 mg/ml 
streptomycin, 50 μM 2-mercaptoethanol, and 4% J558L cell-conditioned 
medium as a source of GM-CSF (change on days 3, 6, and 8) as described 
previously (54). For the diff  erentiation into macrophages, 106 cells/ml were 
cultured for 10 d in DMEM (Sigma-Aldrich) supplemented with 20% horse 
serum and 30% L929 cell-conditioned medium as a source of M-CSF. After 
7 d, cells were washed and recultured in fresh medium for another 3 d. The 
cell preparation contained a homogenous population of macrophages.
For the experiment, the cells were resuspended in medium containing 
0.5% FCS and plated in 96-well microtiter plates (at 105 cells/well) and stimu-
lated upon adherence with TNF. Cell supernatants were harvested after 24 h 
and analyzed directly for cytokine quantifi  cation or stored frozen at −80°C.
DC uptake of OVA-FITC. 100 μg/ml OVA-FITC was added to DC 
cultures at day 12. Cells were incubated for 2 h at 37°C in a humidifi  ed in-
cubator with 5% CO2. Cells were collected, washed three times with cold 2724  IL-17 DOWN-REGULATES ASTHMA | Schnyder-Candrian et al.
PBS containing 1% BSA, and analyzed using a FACS-Calibur-Flow cytom-
eter and CellQuest Software (Becton Dickinson). The markers for the mon-
ovariant histogram (unpublished data) were set based on the negative staining 
control, which was provided by incubating DCs with OVA-FITC at 4°C.
Statistical analysis. The data are presented as the mean ± SD with n = 8 
animals per condition. The signifi  cance of diff  erences between two groups 
was determined by Student t test (two-tailed). Statistical signifi  cance was 
  reported if P < 0.05 was achieved.
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